Year |
Citation |
Score |
2020 |
Li R, Ong SL, Tran LM, Jing Z, Liu B, Park SJ, Huang ZL, Walser TC, Heinrich EL, Lee G, Salehi-Rad R, Crosson WP, Pagano PC, Paul MK, Xu S, et al. Author Correction: Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. Scientific Reports. 10: 4386. PMID 32127587 DOI: 10.1038/S41598-020-61341-3 |
0.312 |
|
2020 |
Li R, Ong SL, Tran LM, Jing Z, Liu B, Park SJ, Huang ZL, Walser TC, Heinrich EL, Lee G, Salehi-Rad R, Crosson WP, Pagano PC, Paul MK, Xu S, et al. Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer. Scientific Reports. 10: 377. PMID 31941995 DOI: 10.1038/S41598-019-57285-Y |
0.347 |
|
2020 |
Kim SS, Xu S, Cui J, Poddar S, Le TM, Hayrapetyan H, Li L, Wu N, Moore AM, Zhou L, Yu AC, Dann AM, Elliott IA, Abt ER, Kim W, et al. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression. Theranostics. 10: 829-840. PMID 31903153 DOI: 10.7150/Thno.40195 |
0.411 |
|
2020 |
Moore AM, Zhou L, Xu S, Donahue TR. Abstract 6045: Interferon signaling induces NAD(H) consumption via PARP9/10/14 and sensitizes pancreatic cancer cells to NAMPT inhibition Cancer Research. 80: 6045-6045. DOI: 10.1158/1538-7445.Am2020-6045 |
0.427 |
|
2019 |
Abt ER, Rosser EW, Durst MA, Lok V, Poddar S, Le TM, Cho A, Kim W, Wei L, Song J, Capri JR, Xu S, Wu N, Slavik R, Jung ME, et al. Metabolic Modifier Screen Reveals Secondary Targets of Protein Kinase Inhibitors within Nucleotide Metabolism. Cell Chemical Biology. PMID 31734178 DOI: 10.1016/J.Chembiol.2019.10.012 |
0.363 |
|
2019 |
Xu S, Herschman HR. A tumor agnostic therapeutic strategy for Hexokinase 1 Null/Hexokinase 2 positive cancers. Cancer Research. PMID 31434645 DOI: 10.1158/0008-5472.Can-19-1789 |
0.44 |
|
2019 |
Xu S, Liu Y, Yang K, Wang H, Shergalis A, Kyani A, Bankhead A, Tamura S, Yang S, Wang X, Wang CC, Rehemtulla A, Ljungman M, Neamati N. Inhibition of protein disulfide isomerase in glioblastoma causes marked downregulation of DNA repair and DNA damage response genes. Theranostics. 9: 2282-2298. PMID 31149044 DOI: 10.7150/Thno.30621 |
0.573 |
|
2019 |
Machiraju PK, Yedla P, Gubbala SP, Bohari T, Abdul JKV, Xu S, Patel R, Chittireddy VRR, Boppana K, Jagarlapudi SARP, Neamati N, Syed R, Amanchy R. Identification, synthesis and evaluation of CSF1R inhibitors using fragment based drug design. Computational Biology and Chemistry. 80: 374-383. PMID 31103918 DOI: 10.1016/J.Compbiolchem.2019.04.015 |
0.597 |
|
2019 |
Elliott IA, Dann AM, Xu S, Kim SS, Abt ER, Kim W, Poddar S, Moore A, Zhou L, Williams JL, Capri JR, Ghukasyan R, Matsumura C, Tucker DA, Armstrong WR, et al. Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion. Proceedings of the National Academy of Sciences of the United States of America. PMID 30894490 DOI: 10.1073/Pnas.1812410116 |
0.417 |
|
2019 |
Xu S, Zhou T, Doh HM, Trinh KR, Catapang A, Lee JT, Braas D, Bayley NA, Yamada RE, Vasuthasawat A, Sasine JP, Timmerman JM, Larson SM, Kim Y, Macleod AR, et al. An HK2 antisense oligonucleotide induces synthetic lethality in HK1-HK2+ multiple myeloma. Cancer Research. PMID 30885978 DOI: 10.1158/0008-5472.Can-18-2799 |
0.43 |
|
2019 |
Xu S, Elliott IA, Dann AM, Kim SS, Abe ER, Kim W, Poddar S, Moore A, Zhou L, Williams JL, Capri JR, Ghukasyan R, Matsumura C, Tucker DA, Armstrong WR, et al. Abstract 4264: Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion Cancer Research. 79: 4264-4264. DOI: 10.1158/1538-7445.Am2019-4264 |
0.426 |
|
2018 |
Xu S, Catapang A, Braas D, Stiles L, Doh HM, Lee JT, Graeber TG, Damoiseaux R, Shirihai O, Herschman HR. A precision therapeutic strategy for hexokinase 1-null, hexokinase 2-positive cancers. Cancer & Metabolism. 6: 7. PMID 29988332 DOI: 10.1186/S40170-018-0181-8 |
0.427 |
|
2018 |
Xu S, Catapang A, Doh HM, Bayley NA, Lee JT, Braas D, Graeber TG, Herschman HR. Hexokinase 2 is targetable for HK1 negative, HK2 positive tumors from a wide variety of tissues of origin. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 29880505 DOI: 10.2967/Jnumed.118.212365 |
0.38 |
|
2017 |
Xu S, Catapang A, Braas D, Stiles L, Lee JT, Graeber TG, Damoiseaux R, Shirihai O, Herschman HR. Abstract B37: Targeting the energy generation triangle to achieve synthetic lethality for treatment of hepatocellular carcinoma Molecular Cancer Therapeutics. 16. DOI: 10.1158/1538-8514.Synthleth-B37 |
0.368 |
|
2016 |
Krall AS, Xu S, Graeber TG, Braas D, Christofk HR. Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor. Nature Communications. 7: 11457. PMID 27126896 DOI: 10.1038/Ncomms11457 |
0.314 |
|
2015 |
Xu S, Adisetiyo H, Tamura S, Grande F, Garofalo A, Roy-Burman P, Neamati N. Dual inhibition of survivin and MAOA synergistically impairs growth of PTEN-negative prostate cancer. British Journal of Cancer. 113: 242-51. PMID 26103574 DOI: 10.1038/Bjc.2015.228 |
0.519 |
|
2015 |
Prevost GP, Garrido M, Xu S, Lefebvre C, Chauchereau A, Carniato D, Briand JF, Gutmann M, Serova M, Tijeras-Raballand A, Grammont AD, Raymond E, Gespach C, Sabbah M, Neamati N, et al. Abstract 4466: New biomarkers to optimize preclinical development of the PDI inhibitor XCE853 Cancer Research. 75: 4466-4466. DOI: 10.1158/1538-7445.Am2015-4466 |
0.483 |
|
2014 |
Singh SS, Sarma JA, Narasu L, Dayam R, Xu S, Neamati N. A review on PARP1 inhibitors: Pharmacophore modeling, virtual and biological screening studies to identify novel PARP1 inhibitors. Current Topics in Medicinal Chemistry. 14: 2020-30. PMID 25262797 DOI: 10.2174/1568026614666140929152123 |
0.577 |
|
2014 |
Xu S, Sankar S, Neamati N. Protein disulfide isomerase: a promising target for cancer therapy. Drug Discovery Today. 19: 222-40. PMID 24184531 DOI: 10.1016/J.Drudis.2013.10.017 |
0.605 |
|
2014 |
Prevost GP, Xu S, Garrido M, Serova M, Vewer OD, Gespach C, Briand J, Tijeras-Raballand A, Gutmann M, Hendrix A, Sabbah M, Chachereau A, Gramont Ad, Neamati N, Carniato D, et al. Abstract 1812: XCE853: A novel PDI inhibitor that inhibits proliferation of human tumor cellsin vitro,ex-vivoandin vivo Cancer Research. 74: 1812-1812. DOI: 10.1158/1538-7445.Am2014-1812 |
0.449 |
|
2013 |
Xu S, Neamati N. gp130: a promising drug target for cancer therapy. Expert Opinion On Therapeutic Targets. 17: 1303-28. PMID 24099136 DOI: 10.1517/14728222.2013.830105 |
0.561 |
|
2013 |
Adisetiyo H, Liang M, Liao CP, Aycock-Williams A, Cohen MB, Xu S, Neamati N, Conway EM, Cheng CY, Nikitin AY, Roy-Burman P. Loss of survivin in the prostate epithelium impedes carcinogenesis in a mouse model of prostate adenocarcinoma. Plos One. 8: e69484. PMID 23936028 DOI: 10.1371/Journal.Pone.0069484 |
0.515 |
|
2013 |
Saha S, Reddy ChV, Xu S, Sankar S, Neamati N, Patro B. Synthesis and SAR studies of marine natural products ma'edamines A, B and their analogues. Bioorganic & Medicinal Chemistry Letters. 23: 5135-9. PMID 23927972 DOI: 10.1016/J.Bmcl.2013.07.017 |
0.515 |
|
2013 |
Xu S, Grande F, Garofalo A, Neamati N. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer. Molecular Cancer Therapeutics. 12: 937-49. PMID 23536726 DOI: 10.1158/1535-7163.Mct-12-1082 |
0.628 |
|
2013 |
Xu S, Oshima T, Imada T, Masuda M, Debnath B, Grande F, Garofalo A, Neamati N. Stabilization of MDA-7/IL-24 for colon cancer therapy. Cancer Letters. 335: 421-30. PMID 23481022 DOI: 10.1016/J.Canlet.2013.02.055 |
0.562 |
|
2013 |
Debnath B, Xu S, Grande F, Garofalo A, Neamati N. Small molecule inhibitors of CXCR4. Theranostics. 3: 47-75. PMID 23382786 DOI: 10.7150/Thno.5376 |
0.569 |
|
2013 |
Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA, Neamati N. Abstract 5513: Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase (PDI) for ovarian cancer treatment. Cancer Research. 73: 5513-5513. DOI: 10.1158/1538-7445.Am2013-5513 |
0.435 |
|
2012 |
Zeng LF, Wang Y, Kazemi R, Xu S, Xu ZL, Sanchez TW, Yang LM, Debnath B, Odde S, Xie H, Zheng YT, Ding J, Neamati N, Long YQ. Repositioning HIV-1 integrase inhibitors for cancer therapeutics: 1,6-naphthyridine-7-carboxamide as a promising scaffold with drug-like properties. Journal of Medicinal Chemistry. 55: 9492-509. PMID 23098137 DOI: 10.1021/Jm300667V |
0.693 |
|
2012 |
Xu S, Butkevich AN, Yamada R, Zhou Y, Debnath B, Duncan R, Zandi E, Petasis NA, Neamati N. Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment. Proceedings of the National Academy of Sciences of the United States of America. 109: 16348-53. PMID 22988091 DOI: 10.1073/Pnas.1205226109 |
0.635 |
|
2012 |
Debnath B, Xu S, Neamati N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. Journal of Medicinal Chemistry. 55: 6645-68. PMID 22650325 DOI: 10.1021/Jm300207S |
0.526 |
|
2012 |
Yamada R, Xu S, Neamati N. Abstract 2908: Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery Cancer Research. 72: 2908-2908. DOI: 10.1158/1538-7445.Am2012-2908 |
0.416 |
|
2012 |
Xu S, Oshima T, Grande F, Neamati N, Garofalo A. Abstract 1927: Mechanistic characterization of SC144 in colon cancer Cancer Research. 72: 1927-1927. DOI: 10.1158/1538-7445.Am2012-1927 |
0.6 |
|
2011 |
Millard M, Pathania D, Grande F, Xu S, Neamati N. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update. Current Pharmaceutical Design. 17: 536-59. PMID 21391905 DOI: 10.2174/138161211795222649 |
0.692 |
|
2011 |
Xu S, Grande F, Garofalo A, Neamati N. Abstract C148: SC144: The first orally active small molecule gp130 inhibitor for the treatment of ovarian cancer. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-C148 |
0.623 |
|
2010 |
Yamada R, Kostova MB, Anchoori RK, Xu S, Neamati N, Khan SR. Biological evaluation of paclitaxel-peptide conjugates as a model for MMP2-targeted drug delivery. Cancer Biology & Therapy. 9: 192-203. PMID 20023432 DOI: 10.4161/Cbt.9.3.10656 |
0.556 |
|
Show low-probability matches. |